The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Latisse     (Z)-7-[(1R,2S,3R,5S)-3,5- dihydroxy-2-[(E...

Synonyms: Lumigan, Bimatoprost, bimatoprostum, AC1NSJUW, Lumigan (TN), ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Lumigan


High impact information on Lumigan


Chemical compound and disease context of Lumigan


Biological context of Lumigan


Anatomical context of Lumigan


Associations of Lumigan with other chemical compounds


Gene context of Lumigan

  • Bimatoprost (nonhydrolyzed amide) also behaved as an FP agonist at the cloned human FP receptor (EC50 = 681 nM), in h-TM (EC50 = 3245 nM) and other cell types [23].
  • Bimatoprost (BMP), which is a highly effective ocular hypotensive agent, is a PGF(2)(alpha) analogue that inhibits both the PGD(2) 11-ketoreductase and PGH(2) 9,11-endoperoxide reductase activities of PGFS [7].
  • Bimatoprost acid exhibited functional activity at the EP1 (EC50 = 2.7 nM) and FP (EC50 = 2.8-3.8 nM in most cells) receptors [23].
  • CONCLUSIONS: An intact FP receptor gene is critical to the IOP response to bimatoprost in the mouse eye [14].
  • Serial IOP measurements were also performed after topical bimatoprost in a separate generation of homozygous FP-knockout mice and wild-type littermate control animals (n = 4 per group) [14].

Analytical, diagnostic and therapeutic context of Lumigan


  1. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Guenoun, J.M., Baudouin, C., Rat, P., Pauly, A., Warnet, J.M., Brignole-Baudouin, F. Invest. Ophthalmol. Vis. Sci. (2005) [Pubmed]
  2. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial. Brandt, J.D., VanDenburgh, A.M., Chen, K., Whitcup, S.M. Ophthalmology (2001) [Pubmed]
  3. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Gandolfi, S.A., Cimino, L. Ophthalmology (2003) [Pubmed]
  4. Bimatoprost-induced periocular skin hyperpigmentation: histopathological study. Kapur, R., Osmanovic, S., Toyran, S., Edward, D.P. Arch. Ophthalmol. (2005) [Pubmed]
  5. The inflow and outflow of anti-glaucoma drugs. Woodward, D.F., Gil, D.W. Trends Pharmacol. Sci. (2004) [Pubmed]
  6. Comparison of prostaglandin F2alpha, bimatoprost (prostamide), and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression. Liang, Y., Li, C., Guzman, V.M., Evinger, A.J., Protzman, C.E., Krauss, A.H., Woodward, D.F. J. Biol. Chem. (2003) [Pubmed]
  7. Prostaglandin F2alpha formation from prostaglandin H2 by prostaglandin F synthase (PGFS): crystal structure of PGFS containing bimatoprost. Komoto, J., Yamada, T., Watanabe, K., Woodward, D.F., Takusagawa, F. Biochemistry (2006) [Pubmed]
  8. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Ota, T., Aihara, M., Narumiya, S., Araie, M. Invest. Ophthalmol. Vis. Sci. (2005) [Pubmed]
  9. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Guenoun, J.M., Baudouin, C., Rat, P., Pauly, A., Warnet, J.M., Brignole-Baudouin, F. Invest. Ophthalmol. Vis. Sci. (2005) [Pubmed]
  10. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Coleman, A.L., Lerner, F., Bernstein, P., Whitcup, S.M. Ophthalmology (2003) [Pubmed]
  11. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Cantor, L.B., WuDunn, D., Cortes, A., Hoop, J., Knotts, S. Survey of ophthalmology. (2004) [Pubmed]
  12. Cystoid macular edema associated with ocular hypotensive lipids. Wand, M., Gaudio, A.R. Am. J. Ophthalmol. (2002) [Pubmed]
  13. Effect of bimatoprost on ocular circulation in patients with open-angle glaucoma or ocular hypertension. Akarsu, C., Yilmaz, S., Taner, P., Ergin, A. Graefes Arch. Clin. Exp. Ophthalmol. (2004) [Pubmed]
  14. Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice. Crowston, J.G., Lindsey, J.D., Morris, C.A., Wheeler, L., Medeiros, F.A., Weinreb, R.N. Invest. Ophthalmol. Vis. Sci. (2005) [Pubmed]
  15. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Maxey, K.M., Johnson, J.L., LaBrecque, J. Survey of ophthalmology. (2002) [Pubmed]
  16. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Brubaker, R.F., Schoff, E.O., Nau, C.B., Carpenter, S.P., Chen, K., Vandenburgh, A.M. Am. J. Ophthalmol. (2001) [Pubmed]
  17. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. Davies, S.S., Ju, W.K., Neufeld, A.H., Abran, D., Chemtob, S., Roberts, L.J. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. (2003) [Pubmed]
  18. Studies using isolated uterine and other preparations show bimatoprost and prostanoid FP agonists have different activity profiles. Chen, J., Senior, J., Marshall, K., Abbas, F., Dinh, H., Dinh, T., Wheeler, L., Woodward, D. Br. J. Pharmacol. (2005) [Pubmed]
  19. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). Woodward, D.F., Krauss, A.H., Chen, J., Liang, Y., Li, C., Protzman, C.E., Bogardus, A., Chen, R., Kedzie, K.M., Krauss, H.A., Gil, D.W., Kharlamb, A., Wheeler, L.A., Babusis, D., Welty, D., Tang-Liu, D.D., Cherukury, M., Andrews, S.W., Burk, R.M., Garst, M.E. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
  20. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Sharif, N.A., Kelly, C.R., Crider, J.Y. Invest. Ophthalmol. Vis. Sci. (2003) [Pubmed]
  21. Upregulation of orphan nuclear receptor Nur77 following PGF(2alpha), Bimatoprost, and Butaprost treatments. Essential role of a protein kinase C pathway involved in EP(2) receptor activated Nur77 gene transcription. Liang, Y., Li, C., Guzman, V.M., Chang, W.W., Evinger, A.J., Pablo, J.V., Woodward, D.F. Br. J. Pharmacol. (2004) [Pubmed]
  22. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Walters, T.R., DuBiner, H.B., Carpenter, S.P., Khan, B., VanDenburgh, A.M. Survey of ophthalmology. (2004) [Pubmed]
  23. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. Sharif, N.A., Kelly, C.R., Crider, J.Y., Williams, G.W., Xu, S.X. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. (2003) [Pubmed]
  24. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Cohen, J.S., Gross, R.L., Cheetham, J.K., VanDenburgh, A.M., Bernstein, P., Whitcup, S.M. Survey of ophthalmology. (2004) [Pubmed]
  25. A Markov modelled pharmacoeconomic analysis of bimatoprost 0.03% in the treatment of glaucoma as an alternative to filtration surgery in Italy. Christensen, T.L., Poulsen, P.B., Holmstrom, S., Walt, J.G., Vetrugno, M. Current medical research and opinion. (2005) [Pubmed]
WikiGenes - Universities